vs
Side-by-side financial comparison of NATURES SUNSHINE PRODUCTS INC (NATR) and ServisFirst Bancshares, Inc. (SFBS). Click either name above to swap in a different company.
ServisFirst Bancshares, Inc. is the larger business by last-quarter revenue ($159.0M vs $123.8M, roughly 1.3× NATURES SUNSHINE PRODUCTS INC). ServisFirst Bancshares, Inc. runs the higher net margin — 52.2% vs 3.3%, a 48.9% gap on every dollar of revenue. Over the past eight quarters, ServisFirst Bancshares, Inc.'s revenue compounded faster (17.7% CAGR vs 5.6%).
Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.
ServisFirst Bancshares, Inc. is a U.S.-based bank holding company operating full-service banking locations primarily across the Southeastern United States. It offers a full suite of commercial banking, consumer banking, wealth management, and mortgage lending services to small and medium-sized businesses, professional clients, and individual consumers.
NATR vs SFBS — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $123.8M | $159.0M |
| Net Profit | $4.1M | $83.0M |
| Gross Margin | 72.5% | — |
| Operating Margin | 4.3% | — |
| Net Margin | 3.3% | 52.2% |
| Revenue YoY | 4.7% | — |
| Net Profit YoY | 1379.4% | 31.2% |
| EPS (diluted) | $0.23 | $1.52 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $159.0M | ||
| Q4 25 | $123.8M | $162.2M | ||
| Q3 25 | $128.3M | $136.3M | ||
| Q2 25 | $114.8M | $132.1M | ||
| Q1 25 | $113.2M | $131.8M | ||
| Q4 24 | $118.2M | $131.9M | ||
| Q3 24 | $114.6M | $123.7M | ||
| Q2 24 | $110.6M | $114.8M |
| Q1 26 | — | $83.0M | ||
| Q4 25 | $4.1M | $86.4M | ||
| Q3 25 | $5.3M | $65.6M | ||
| Q2 25 | $5.3M | $61.4M | ||
| Q1 25 | $4.7M | $63.2M | ||
| Q4 24 | $-321.0K | $65.2M | ||
| Q3 24 | $4.3M | $59.9M | ||
| Q2 24 | $1.3M | $52.1M |
| Q1 26 | — | — | ||
| Q4 25 | 72.5% | — | ||
| Q3 25 | 73.3% | — | ||
| Q2 25 | 71.7% | — | ||
| Q1 25 | 72.1% | — | ||
| Q4 24 | 72.0% | — | ||
| Q3 24 | 71.3% | — | ||
| Q2 24 | 71.4% | — |
| Q1 26 | — | — | ||
| Q4 25 | 4.3% | 66.3% | ||
| Q3 25 | 7.0% | 57.8% | ||
| Q2 25 | 3.7% | 58.0% | ||
| Q1 25 | 5.4% | 60.0% | ||
| Q4 24 | 3.8% | 60.2% | ||
| Q3 24 | 4.6% | 58.5% | ||
| Q2 24 | 5.1% | 58.0% |
| Q1 26 | — | 52.2% | ||
| Q4 25 | 3.3% | 59.0% | ||
| Q3 25 | 4.2% | 48.1% | ||
| Q2 25 | 4.6% | 46.5% | ||
| Q1 25 | 4.2% | 48.0% | ||
| Q4 24 | -0.3% | 52.9% | ||
| Q3 24 | 3.8% | 48.4% | ||
| Q2 24 | 1.2% | 45.4% |
| Q1 26 | — | $1.52 | ||
| Q4 25 | $0.23 | $1.58 | ||
| Q3 25 | $0.30 | $1.20 | ||
| Q2 25 | $0.28 | $1.12 | ||
| Q1 25 | $0.25 | $1.16 | ||
| Q4 24 | $-0.02 | $1.19 | ||
| Q3 24 | $0.23 | $1.10 | ||
| Q2 24 | $0.07 | $0.95 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $93.9M | $1.8B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $161.6M | $1.9B |
| Total Assets | $261.1M | $18.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $1.8B | ||
| Q4 25 | $93.9M | — | ||
| Q3 25 | $95.6M | — | ||
| Q2 25 | $81.3M | — | ||
| Q1 25 | $86.5M | — | ||
| Q4 24 | $84.7M | — | ||
| Q3 24 | $78.7M | — | ||
| Q2 24 | $68.7M | — |
| Q1 26 | — | $1.9B | ||
| Q4 25 | $161.6M | $1.8B | ||
| Q3 25 | $166.7M | $1.8B | ||
| Q2 25 | $163.7M | $1.7B | ||
| Q1 25 | $167.1M | $1.7B | ||
| Q4 24 | $161.0M | $1.6B | ||
| Q3 24 | $162.6M | $1.6B | ||
| Q2 24 | $156.4M | $1.5B |
| Q1 26 | — | $18.2B | ||
| Q4 25 | $261.1M | $17.7B | ||
| Q3 25 | $264.8M | $17.6B | ||
| Q2 25 | $254.9M | $17.4B | ||
| Q1 25 | $252.7M | $18.6B | ||
| Q4 24 | $240.9M | $17.4B | ||
| Q3 24 | $245.3M | $16.4B | ||
| Q2 24 | $235.8M | $16.0B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.9M | — |
| Free Cash FlowOCF − Capex | $7.6M | — |
| FCF MarginFCF / Revenue | 6.1% | — |
| Capex IntensityCapex / Revenue | 1.9% | — |
| Cash ConversionOCF / Net Profit | 2.41× | — |
| TTM Free Cash FlowTrailing 4 quarters | $28.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $9.9M | $355.2M | ||
| Q3 25 | $18.5M | $140.9M | ||
| Q2 25 | $4.3M | $67.6M | ||
| Q1 25 | $2.6M | $48.0M | ||
| Q4 24 | $12.2M | $252.9M | ||
| Q3 24 | $9.6M | $84.0M | ||
| Q2 24 | $1.3M | $48.3M |
| Q1 26 | — | — | ||
| Q4 25 | $7.6M | — | ||
| Q3 25 | $16.8M | — | ||
| Q2 25 | $3.0M | — | ||
| Q1 25 | $1.5M | — | ||
| Q4 24 | $10.0M | — | ||
| Q3 24 | $7.9M | — | ||
| Q2 24 | $-2.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | 6.1% | — | ||
| Q3 25 | 13.1% | — | ||
| Q2 25 | 2.6% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 8.5% | — | ||
| Q3 24 | 6.9% | — | ||
| Q2 24 | -1.9% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.2% | — | ||
| Q1 25 | 1.0% | — | ||
| Q4 24 | 1.9% | — | ||
| Q3 24 | 1.5% | — | ||
| Q2 24 | 3.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | 2.41× | 4.11× | ||
| Q3 25 | 3.46× | 2.15× | ||
| Q2 25 | 0.81× | 1.10× | ||
| Q1 25 | 0.55× | 0.76× | ||
| Q4 24 | — | 3.88× | ||
| Q3 24 | 2.21× | 1.40× | ||
| Q2 24 | 0.97× | 0.93× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
SFBS
| Net Interest Income | $148.1M | 93% |
| Noninterest Income | $10.8M | 7% |
